Navigation Links
Stem cell transplant in mouse embryo yields heart protection in adulthood
Date:5/14/2009

Rochester, Minn. May 14, 2009 - Stem cells play a role in heart muscle rejuvenation by attracting cells from the body that develop into heart muscle cells. They have been successfully used to halt or reverse cardiac injury following heart attack, but not to prevent injury before it occurs.

A new study that delivered embryonic stem cells to mouse embryos in the earliest stages of development found that the resulting mice demonstrated a capacity to recover from cardiac injury in adulthood. The study, which provides the first evidence that preventive regenerative medicine can successfully be used to treat myocardial infarction through prophylactic intervention, is published in Stem Cells.

Led by Dr. Andre Terzic of the Mayo Clinic, researchers injected mouse embryos with embryonic stem cells that had been used to successfully treat ischemic heart disease following heart attack. The resulting animals incorporated between five and 20 percent of labeled stem cell-derived tissue. They were born with no apparent abnormalities, and the tested and control groups had similar overall baseline cardiac disease risk profiles. They also demonstrated similar cardiac performance during the one year follow-up.

Researchers induced cardiac injury in both groups by tying off the left anterior artery, causing complete coronary blockage. The group that had received the embryonic stem cell treatment recovered cardiac function, while the other group deteriorated, demonstrating ischemic myopathy, myocardial scarring and significant pulmonary congestion, which are typically seen in the progression towards heart failure. Overall, the group treated with stem cells displayed a favorable disease course, with superior exercise workload capacity and stress test performance, as well as increased survival.

"Preemptive stem cell-based intervention in utero thus provides a strategy to engineer tolerance, and prevent incidence of life-threatening organ failure in the adult," the authors state. In utero therapy was introduced 30 years ago to treat congenital defects and has been used successfully since then to improve outcomes after birth, but this study takes the concept one step further.

"In this way, prenatal transplantation of embryonic stem cells expands the scope of traditional retrospective therapy to the previously unexplored prospective protection," the authors note. They conclude that beyond reconstructive surgery, stem cell transplantation in prenatal development could offer an innovative approach for preventing disease.

"This study expands the scope of stem cell therapy including traditional retrospective and preventive cell therapy," says Miodrag Stojković, co-editor of the journal. "Therefore, Stem Cells is very proud to publish this pioneering work which is the very first proof of principle for prevention of adult heart stress intolerance to ischemic injury through preemptive cell based intervention."


'/>"/>

Contact: Sean Wagner
journalnews@bos.blackwellpublishing.net
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher at 6 Months Than BiVADS and LVADs
2. Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
3. United Spinal Association Reports Positive Results of Stem Cell Transplantation to Treat Multiple Sclerosis: Study May be Key to Unlocking a Cure
4. First U.S. Face Transplant Recipient Recounts Ordeal
5. Total Artificial Heart Patient 3rd in the World to Receive Dual Transplants
6. Hair Transplant Office Expands Serviceable Area
7. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
8. Organ Donor Families, Transplant Recipients Journey to State Capitol to Urge Passage of Key Donor Designation Legislation
9. HIV positive and HIV negative patients have similar survival rates following liver transplant
10. UBC research finds molecular "key" to successful blood stem cell transplants
11. Majority of doctors skeptical of organ transplantation practices in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: